| |
Course Number |
Course Title |
Guest |
|
| |
15.966 |
Managing in Adversity |
Daniel Vasella
CEO, Novartis |
|
| |
15.966 |
Managing in Adversity |
Richard Pops
CEO, Alkermes |
|
| |
15.966 |
Managing in Adversity |
Gabriel Schmergel
Retired President/CEO
Genetics Institute, Inc |
|
| |
15.398 |
Corporations at the Crossroads |
Jim Tobin
President and CEO, Boston Scientific |
|
| |
15.390 |
New Enterprises |
Tuan Ha Ngoc
CEO, AVEO Pharmaceuticals |
|
| |
15.390 |
New Enterprises |
Samir Kaul
Partner, Flagship Ventures |
|
| |
SIP RF.478 |
Future for Biogenerics and Healthcare Costs |
James Green
Sr Vice President, Biogen Idec |
|
| |
SIP RF.478 |
Future for Biogenerics and Healthcare Costs |
Suzanne Sensabaugh
Sr Director, TEVA-USA |
|
| |
SIP RF.478 |
Future for Biogenerics and Healthcare Costs |
Ashoke Bhattacharjya
Exec Director, Johnson & Johnson |
|
| |
SIP RF.478 |
Future for Biogenerics and Healthcare Costs |
John A. Fallon
Exec and Sr Vice President, BCBS of MA |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
Jonathan Flemming
Managing Partner, Oxford Bioscience Partners |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
Ron Zwanzinger
CEO, Inverness Medical Sciences |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
John Sullivan
Director, Leerink Swann & Company |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
Ted Ashburn
Senior Director of Business Development
Dynogen Pharmaceuticals |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
John Maraganore
CEO, Alnylam Pharmaceuticals |
|
| |
15.363 |
Strategic Decision Making in BioMedical Business |
Andrey Zarur
Serial Entrepreneur and CEO, BioProcessors |
|
| |
HST.987 |
Case Studies and Strategies in Drug Development and Discovery |
Peter Farina
Boehringer Ingelheim |
|
| |
HST.987 |
Case Studies and Strategies in Drug Development and Discovery |
Julian Adams
CSO, Infinity Pharmaceuticals |
|
| |
HST.987 |
Case Studies and Strategies in Drug Development and Discovery |
Andreas Jessel
Sanofi-Aventis |
|
| |
HST.987 |
Case Studies and Strategies in Drug Development and Discovery |
Jeff Hanke
Astra Zeneca |
|
| |
HST.987 |
Case Studies and Strategies in Drug Development and Discovery |
Burt Adelman
Biogen Idec |
|